Welcome to our dedicated page for Aravive news (Ticker: ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive stock.
This page contains historical news coverage for Aravive Inc (ARAV), which operated as a clinical-stage biopharmaceutical company focused on oncology drug development. Aravive specialized in developing batiraxcept, a targeted therapy for platinum-resistant ovarian cancer that inhibits the GAS6-AXL signaling pathway. The company delisted from the Nasdaq Stock Market and no longer trades on major exchanges.
Historical news coverage includes clinical trial results from Phase 3 studies, FDA regulatory milestones such as Fast Track and Orphan Drug designations, investor presentations at healthcare conferences, and corporate developments including financing activities and personnel changes. This archive documents the company's progression from clinical development through its delisting, providing context on the challenges faced by clinical-stage biotech companies advancing novel cancer therapies.
Browse this news archive to understand Aravive's clinical development strategy, regulatory pathway, and the business decisions that shaped its trajectory in the competitive oncology therapeutics market.
